Apr 3, 2023  |  4:00pm - 5:00pm
Monday seminar series

Translating Gene Expression into Clinical Care for Breast Cancer and Sarcomas (7th Emmanuel Farber Lectureship)

Disruptive Innovation

As part of our Monday seminar series, and for the 7th Emmanuel Farber Lectureship, we are delighted to welcome our speaker:

Torsten O. Nielsen MD/PhD FRCPC
Professor of Pathology & Laboratory Medicine
MD/PhD Program Director, Faculty of Medicine
University of British Columbia

Hosted By

Dr. Susan Done

How to join

The event will be in person and live on zoom, no need to register.

MSB 2170 for in person, followed by a reception.

To join on zoom

Passcode: 569766

Medical Sciences Building
University of Toronto
1 King’s College Circle
Toronto, ON  M5S 1A8 

Details are sent to the LMP community in the Friday events bulletin.

If you have any questions about this event, please contact Louella D'Cunha at lmp.undergrad@utoronto.ca

Speaker: Dr. Torsten O. Nielsen

Torsten O. Nielsen is a Professor of Pathology and Laboratory Medicine at the University of British Columbia. After completing the combined MD/PhD program at McGill, he undertook training in England, Stanford and the Cleveland Clinic before taking a position as a clinician-scientist surgical pathologist, specializing in sarcomas and breast cancer.

His contributions in sarcomas include the world's first large scale microarray studies of sarcomas; developing diagnostic tests including DOG-1, TLE1 and nanoString-based molecular panels; identifying the molecular biology driving tenosynovial giant cell tumors, synovial sarcoma and epithelioid sarcoma; and involvement in clinical trials for these tumor types.

In breast cancer, Prof. Nielsen has published a series of well-cited studies applying molecular subtyping biomarkers onto large tissue microarray series. In doing so, he has worked to improve and standardize immunohistochemical tests for estrogen receptor, basal biomarkers, and Ki67, the latter as part of a dedicated international consortium. With funding from the NIH Strategic Partnering to Evaluate Cancer Signatures, he is a co-inventor of the PAM50 breast cancer intrinsic subtyping test to the point of FDA clearance as an internationally-distributed test.

Prof. Nielsen is also involved in the training of a new generation of clinician-scientists in his role as director of the MD/PhD program at UBC.

Torsten O. Nielsen